"Utilized for monitoring COVID Patients"
Used in 500 medical institutions across 14 countries

Young Juhn CEO introducing S-Patch on 'Wellysis Partners Day'

Wellysis 'S-Patch Cardio' is a wearable ECG monitor that diagnoses cardiovascular diseases using artificial intelligence (AI) technology. Its distinctive features include more than doubling the monitoring time compared to conventional monitors and significantly improving portability. Wellysis held the '2021 Wellysis Partners Day' at the Samsung SDS headquarters in Jamsil, Seoul on the 28th to introduce use cases of S-Patch Cardio.

S-Patch Cardio is a product developed by the Samsung SDS Digital Healthcare team, combining Samsung SDS' analytical technology and AI program technology with Samsung Electronics' bioprocessor chip. By attaching the patch to the skin near the heart, it allows remote monitoring of ECG for up to 100 hours. With a weight of around 8g, the product is convenient for daily use. Following the successful commercialization of this product in 2018, the team spun off Wellysis in May 2019. 

This Partners Day event, conducted via online streaming, marked the first event since the founding of Wellysis. Over 200 representatives from 14 countries, including partner companies, hospitals, and research institutions, participated. Dr. Ryan Kellogg, Research Director at Standford University School of Medicine, introduced cases of utilizing S-Patch Cardio in a project involving 1,000 recovered COVID-19 patients. He stated, "The most fatal thing for COVID-19 recovered patients is cardiovascular diseases," and emphasized that they are conducting meaningful research by continuously monitoring patietns' ECG with S-Patch Cardio.
 

Adam Williams, CEO of S-Patch Cardio's distributor in Australia, shared cases from Australia where medical institutions monitor and diagnose cardiac patients living in remote areas using this product. He mentioned, "Recently, the excellence of S-Patch Cardio solution was highlighted on Australia's Channel 7 news."

Young Juhn, CEO of Wellysis, emphasized, "S-Patch Cardio has received medical certifications in 14 countries and has proven its technological capability and reliability by being used in 500 medical institutions within approximately two years since its launch." A representative from the domestic distributor, Samjin Pharmaceuticals, stated, "S-Patch Cardio is widely used from primary to tertiary hospitals in Korea, including health check-ups."

Wellysis also unveiled its new product, "S-Patch Ex", on this event. S-Patch Ex enhances diagnostic performance by expanding the ECG sensors and improving compatibility between devices and software. After recently obtaining certification from the Ministry of Food and Drug Safety and CE certification in Europe, it will be first launched in the domestic market in the first half of this year and exported starting from July. The CEO stated, "We will continue to release new and upgraded solutions in medical devices, software, AI, and more in the future."